Neuromuscular Disease News

Amylyx Pharmaceuticals Inc. announced Relyvrio, its amyotrophic lateral sclerosis therapeutic, will be removed from the market in the United States and Canada, effective immediately.

A Cincinnati-based life sciences company announced that one of its development candidates, ASHA-624, will be advanced as a potential disease modifying therapy for amyotrophic lateral sclerosis.

March is Multiple Sclerosis Awareness Month, a time to improve knowledge of and highlight the growing treatment options for progressive types of this degenerative disease.

A Boston-area developer of brain-computer interface technology and a Canadian biotech firm have announced a collaboration to globally commercialize the former’s brain health tools.

The FDA has approved Duvyzat for the treatment of Duchenne muscular dystrophy among patients aged 6 years and older, according to a press release.

The FDA has approved breakthrough device designation for a novel neuroimmune modulation platform for those with relapsing-remitting multiple sclerosis, according to the manufacturer.

Agamree oral suspension 40 mg/mL is now commercially available in the United States for the treatment of Duchenne muscular dystrophy in patients aged 2 years and older, according to a press release.

Artificial intelligence-based diagnostic tools may be valuable in accurately tracking myasthenia gravis symptoms and mitigating disease risk, according to a poster at the 2024 MDA Clinical & Scientific Conference.

Enzyme-replacement therapy may slow disease progression and improve motor function in children with Pompe disease, according to a poster from the 2024 Muscular Dystrophy Association Clinical & Scientific Conference.

Treatment with nusinersen was linked to increased motor function and reduction of the neurodegenerative biomarker neurofilament light chain in children with spinal muscular atrophy, according to interim results of a study.